Form 4: Haemonetics Director Claire Pomeroy Receives Equity Grant

Haemonetics Corporation's Director, Claire Pomeroy, was granted 2,693 restricted stock units as part of the company's long-term incentive plan.

Summary

• Claire Pomeroy, a Director of Haemonetics Corp (HAE), acquired 2,693 shares of common stock.
• The acquisition was in the form of Restricted Stock Units (RSUs) on July 24, 2025.
• These RSUs were issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs are scheduled to vest 100% on the first anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
• Following this transaction, Claire Pomeroy beneficially owns 16,872 shares directly.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard compensation practices.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their interests with long-term shareholder value.
• The transaction is part of a pre-existing, approved long-term incentive compensation plan, indicating standard corporate governance practices.

Future Outlook

NA

Industry Context

This is a routine insider transaction for compensation, common across all industries for public companies, reflecting standard executive and director incentive structures. It does not provide specific industry-wide insights.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a common practice in corporate governance across various industries, including the medical technology sector where Haemonetics operates.
• Many companies, such as Medtronic (MDT) or Baxter International (BAX), utilize similar equity-based compensation plans to align director and executive interests with long-term shareholder value.
• The vesting schedule of 100% on the first anniversary of the grant date is a standard approach for director RSU awards, often tied to continued service.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units (RSUs) to Claire Pomeroy, a Director of Haemonetics Corp, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The granted Restricted Stock Units (RSUs) are expected to vest 100% on the first anniversary of the grant date, which is July 24, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director. While it signifies alignment of interests, it is not a material event that would typically warrant a change in investment recommendation. The transaction is standard practice and does not provide new information to suggest a 'buy' or 'sell' action.

Keywords

Haemonetics Corp, HAE, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Claire Pomeroy